SCHEDULE 13D: Sponsor and CEO Disclose 12.5% Stake in Drugs Made In America Acquisition Corp. via Schedule 13D Filing

Drugs Made In America Acquisition LLC and its managing member, Lynn Stockwell, have filed a Schedule 13D disclosing a 12.5% beneficial ownership stake in Drugs Made In America Acquisition Corp., totaling 4,188,780 ordinary shares.

Summary

• Drugs Made In America Acquisition LLC (the "Sponsor") and Lynn Stockwell (sole managing member, CEO, and Executive Chair) are the reporting persons in this Schedule 13D filing.
• They collectively beneficially own 4,188,780 ordinary shares of Drugs Made In America Acquisition Corp., representing 12.5% of the Issuer's total ordinary shares issued and outstanding.
• This percentage is calculated based on 33,517,143 ordinary shares issued and outstanding.
• The reported ownership includes 430,000 ordinary shares underlying 430,000 units, with each unit comprising one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination.
• The Sponsor initially acquired 22,361,111 ordinary shares for an aggregate purchase price of $35,000 on June 17, 2024.
• On November 6, 2024, the Sponsor surrendered and forfeited 12,503,968 ordinary shares to the Issuer for no consideration.
• Simultaneously with the closing of the Issuer's initial public offering on January 29, 2025, the Sponsor acquired 400,000 private units at $10 per unit, totaling $4,000,000.
• An additional 30,000 private units were acquired by the Sponsor for $300,000 on February 18, 2025, following the underwriters' full exercise of the over-allotment option.
• The Reporting Persons acquired these shares for investment purposes and intend to continuously review their investment in the Issuer.
• They may, in the future, acquire additional securities, sell existing holdings, engage with management and the Board, discuss with other shareholders, or propose changes to the Issuer's capitalization, ownership, board structure, or business combinations.

Sentiment

Score: 6

Explanation: The document is a factual disclosure of beneficial ownership and related agreements. The significant insider stake and commitment to funding are positive indicators of alignment, but the historical forfeiture of shares and transfers to other insiders for low/no consideration introduce some minor negative aspects. Overall, it's a standard SPAC sponsor disclosure, leaning slightly positive due to the clear commitment to the Issuer's future.

Positives

• Significant insider ownership of 12.5% by the Sponsor and CEO, Lynn Stockwell, aligns their interests directly with the long-term success and value creation for shareholders.
• The Sponsor has committed to providing up to $1,100,000 in working capital loans to the Issuer, convertible into private units, demonstrating financial support for the company's operations and future business combination efforts.
• The Reporting Persons have agreed to vote their shares in favor of the Issuer's initial business combination, providing a stable voting bloc for key strategic decisions.
• A lock-up period is in place for founder shares and private units, preventing immediate large-scale sales by insiders post-business combination and potentially stabilizing the share price.

Negatives

• The Sponsor surrendered a substantial 12,503,968 ordinary shares for no consideration on November 6, 2024, which could indicate a significant restructuring of initial equity or a re-evaluation of the Sponsor's initial stake.
• The initial acquisition of 22,361,111 ordinary shares by the Sponsor for only $35,000 represents a very low cost basis for founder shares, which can lead to significant dilution for public shareholders if not offset by substantial value creation.
• The Sponsor transferred 400,000 ordinary shares to officers and directors for no consideration and an additional 5,698,363 ordinary shares for consideration ranging from no consideration to $1.50 per share, which could be perceived as preferential treatment for insiders or a form of dilution for other shareholders.

Risks

• The value of the rights to receive one-eighth (1/8) of an ordinary share is contingent upon the consummation of an initial business combination, introducing uncertainty regarding their ultimate value.
• The Sponsor's agreement to surrender up to 110,000 private units if working capital loans are less than $1,100,000 introduces a risk of forfeiture of units, which could impact the Sponsor's overall equity stake.
• The lock-up period for founder shares and private units has specific conditions for release (e.g., six months post-business combination or share price reaching $12.50), which could lead to a significant increase in the tradable float once these shares are released, potentially impacting market price.
• The Issuer's ability to complete an initial business combination within the specified 'completion window' is critical; failure to do so would result in liquidation, impacting the value of shares, particularly for founder and private shares where redemption rights are waived.

Future Outlook

The Reporting Persons acquired the shares for investment purposes and intend to continuously review their investment in the Issuer. Depending on various factors including the Issuer's financial position, investment strategy, share price levels, market conditions, and general economic and industry conditions, the Reporting Persons may in the future take actions such as acquiring additional securities, selling existing holdings, engaging in communications with management and the Board of Directors, discussing with other shareholders or third parties about the Issuer, proposing changes to the Issuer's capitalization, ownership structure, board structure (including composition), potential business combinations or dispositions, or suggesting improvements to the Issuer's financial and/or operational performance.

Management Comments

• Lynn Stockwell, serving as Chief Executive Officer and Executive Chair of the board of directors of the Issuer, may exert influence over the corporate activities of the Issuer, including those related to strategic initiatives and potential business combinations.

Industry Context

This Schedule 13D filing is a standard disclosure for a Special Purpose Acquisition Company (SPAC) where the sponsor and key management report their beneficial ownership. Such filings are crucial for transparency, detailing insider stakes and their commitment to the SPAC's primary objective of identifying and completing an initial business combination. The financial structure involving founder shares, private units, and working capital loan commitments is typical for SPACs, designed to align the sponsor's financial interests with the successful execution of the de-SPAC transaction and subsequent value creation for shareholders.

Corporate Governance

Related Party Transactions

• The Issuer issued 22,361,111 ordinary shares to Drugs Made In America Acquisition LLC (the sponsor) for an aggregate purchase price of $35,000 on June 17, 2024.
• The sponsor acquired 400,000 private units from the Issuer for $4,000,000 on January 29, 2025, and an additional 30,000 private units for $300,000 on February 18, 2025.
• The sponsor agreed to provide the Issuer up to $1,100,000 in working capital loans, convertible into private units at $10.00 per unit.
• The sponsor transferred 400,000 ordinary shares to certain of the Issuer's officers and directors for no consideration as of January 29, 2025.
• The sponsor transferred an aggregate of 5,698,363 ordinary shares for consideration ranging from no consideration to $1.50 per share as of January 29, 2025.

Stakeholder Impact

• Shareholders: The significant beneficial ownership by the sponsor and CEO aligns their interests with public shareholders in seeking a successful business combination. The lock-up period provides some assurance against immediate insider selling post-combination. However, the initial low cost basis of founder shares and transfers to other insiders for low/no consideration could be a point of concern regarding potential future dilution or preferential treatment.
• Management/Board: Lynn Stockwell's dual role as CEO and Executive Chair, combined with her beneficial ownership, grants her significant influence over the company's strategic direction and corporate activities.
• Creditors: The commitment for working capital loans provides a source of funding for the Issuer's operations, potentially reducing immediate reliance on external debt.

Next Steps

• Consummation of the Issuer's initial business combination.
• Potential future acquisition or sale of additional securities by the Reporting Persons.
• Potential engagement in communications with the Issuer's management and Board of Directors.
• Potential discussions with other shareholders or third parties regarding the Issuer and the Reporting Persons' investment.
• Potential recommendations or proposals to the Issuer concerning changes to capitalization, ownership structure, board structure, or potential business combinations/dispositions.
• Potential suggestions for improving the Issuer's financial and/or operational performance.

Key Dates

Keywords

Drugs Made In America Acquisition Corp., Schedule 13D, Beneficial Ownership, Lynn Stockwell, Drugs Made In America Acquisition LLC, SPAC, Special Purpose Acquisition Company, Ordinary Shares, Private Units, IPO, Initial Business Combination, Corporate Governance, Investment Strategy, SEC Filing